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Highlights 
¥ What is already known about the topic?!The potential for MCDA to support HTA has been 
much discussed, and various HTA agencies are piloting or applying MCDA. Alongside these 
developments, good practice guidelines for the application of MCDA in healthcare have been 
developed. 
¥ What does the paper add to existing knowledge?!An assessment of!current applications of 
MCDA to HTA in light of good practice guidelines reveals that many have methodological 
flaws that undermine their usefulness. 
¥ What insights does the paper provide for informing health care-related decision making?!More 
attention needs to be paid to MCDA good practice by researchers, journal editors and 
decision makers and further methodological developments are required if MCDA is to achieve 
its potential to support HTA.!
 
Abstract  
The potential for MCDA to support HTA has been much discussed, and various HTA agencies are 
piloting or applying MCDA. Alongside these developments, good practice guidelines for the 
application of MCDA in healthcare have been developed. An assessment of!current applications of 
MCDA to HTA in light of good practice guidelines reveals, however, that many have methodological 
flaws that undermine their usefulness. Three challenges are considered: the use of additive models, a 
lack of connection between criteria scales and weights, and the use of MCDA in economic evaluation. 
More attention needs to be paid to MCDA good practice by researchers, journal editors and decision 
makers and further methodological developments are required if MCDA is to achieve its potential to 
support HTA. 
 
Introduction 
Multi-criteria decision analysis (MCDA) is proposed as part of health technology assessment (HTA) 
because it offers the means to consider a more comprehensive set of benefits than conventional HTA 
methods, while still summarising these benefits in a single number. MCDA has been adopted or 
piloted by various HTA agencies, including in Germany[1], Italy[2], Hungary[3], Colombia[2], and 
Thailand[4]. While MCDA has the potential to make a contribution to HTA, we are concerned that it is 
failing to do so because applications are ignoring some key principles. We focus on three challenges: 
the use of additive models, a lack of connection between criteria scales and weights, and the use of 
MCDA in economic evaluation. Many of the concerns raised are already recognized in the literature[5, 
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6]. This commentary highlights and illustrates the implications of these concerns through a discussion 
of a recent application of a well-known MCDA for HTA1, the EVIDEM framework[7] (from here on 
referred to as ‘the illustration’, see Table 1 for more detail), but the concerns are applicable to many 
examples of MCDA in HTA. 
The Use of Additive Value Models 
By far the most prevalent model adopted for HTA MCDAs is the additive one[6]. This involves a 
simple weighted sum of the criteria scores. An additive model is analytically simple, facilitating 
implementation and transparency, but it requires that the criteria do not overlap (otherwise there will 
be inappropriate double counting of value) and are preferentially independent (the weight attached to 
one criterion should not depend on the performance on other criteria).  
Unfortunately, many applications of the additive model in HTA violate these requirements. For 
instance, in the illustration (Table 1) overlap results from the inclusion of cost-effectiveness alongside 
other cost and effectiveness criteria. Over 40% of MCDAs designed to support ‘coverage or 
reimbursement’ decisions include this overlap[8]. The overlap between these two criteria would be 
avoided by removing one of them from the MCDA. However, below we advocate removing both of 
them.  
Another source of overlap in the illustration is the inclusion of both ‘improvement in patient-reported 
outcomes (PROs)’ and ‘improvement in efficacy or effectiveness’. While PROs may provide extra 
information on outcomes of importance to patients, combining this additively with efficacy or 
effectiveness requires that the weights attached acknowledge the overlap. The weight attached to 
‘improvement in PROs’ must reflect only the extra value associated with this criterion, over and above 
that already captured in ‘improvement in efficacy or effectiveness’. Eliciting such complex weights 
would put significant additional cognitive burden on stakeholders. In the presence of such overlap, 
good practice guidelines recommend re-structuring the criteria set, which can involve re-defining or 
removing criteria[6]. If the overlap cannot be completely avoided, the MCDA can be run more than 
                                                             
1 The application was chosen as the most recent publication of the use of EVIDEM available on the EVIDEM 
website (https://www.evidem.org) at the time of writing the paper. Other applications of the framework may vary 
in, for instance, the criteria selected and the weighting method adopted. 
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once, each time just including one of the overlapping criteria, to test whether the different designs 
generate the same result[6]. 
Although violation of preferential independence has received less attention in the HTA-MCDA 
literature, it is perhaps of greater concern, and the broader literature on valuing health provides 
support for the idea that MCDAs often violate this requirement. For instance, Nord’s work on how the 
value of a particular health gain varies with the underlying disease severity points to a potential 
preferential dependence of these criteria[9]. However, over 40% of MCDAs designed to support 
reimbursement or coverage decisions included severity alongside health gain in an additive model[8]. 
If the value of a health gain varies with disease severity, then its weight will depend on severity level, 
implying preferential dependence and making an additive model inappropriate.  
The illustration shows how preferential dependence undermines the validity of additive models. 
Consider an intervention, say a placebo that scores zero on ‘improvement in efficacy or 
effectiveness’. Although most would consider such an intervention to have very low value, the additive 
model can still lead to a high one—a possible overall score up to 0.914 out of 1, depending on 
performance on other criteria2. A placebo with no health gain, but well tolerated and for a severe 
disease, would be preferred to an intervention with high health gain but minor safety risks for a less 
severe disease. Concerned to avoid designs that generate such a result, Morton proposes the ‘treacle 
test’ for an MCDA—that a completely ineffective treatment should not win[10]. 
A related source of preferential dependence in the illustration results from the inclusion of both 
‘comparator intervention limitations’ and ‘improvement in efficacy’. The value of ‘major improvement in 
efficacy’ is dependent on baseline health, which is partly a function of the performance of existing 
treatment. The illustration puts a similar value on moving from a lower improvement in efficacy to a 
major improvement in efficacy (0.086) as investing in a treatment whose comparator has major 
limitations rather than one for which the comparator has no limitations (0.074). However, in 
combination these criteria produce spurious outcomes because their interaction has not been 
considered in the design of the MCDA – the model is almost indifferent between investing in a 
                                                             
2 If an intervention achieved the highest performance on all other criteria except for ‘improvement in efficacy or 
effectiveness’, given the weights attached to those criteria, it would in an additive model attain a value of 0.914, 
even if it receive a score of -3 and thus a partial value of 0 on ‘improvement in efficacy or effectiveness’. It is 
possible that poor performance on ‘improved efficacy or effectiveness’ might also be reflected in a less than 
perfect performance on other criteria, such as ‘public health interest’, ‘improvement in PROs’ or ‘clinical 
guidelines’. This isn’t clear, but the possibility points to sources of overlap in the framework. 
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treatment that produces little improvement over a comparator that is not effective (0 + 0.074), and 
investing in a treatment that is a major improvement over a comparator that is already effective (0.086 
+ 0).  
Further work is required to determine what should be done in the presence of preferential 
dependence. Good practice guidelines would suggest that it should either be removed by 
restructuring the criteria set and maintaining an additive model, or that the additive model is invalid 
and a multiplicative or multilinear model should be adopted[6]. These models allow translating zero 
health gain into an overall zero score, as well as incorporating other interaction effects into the value 
model. At the heart of the illustration is the idea that issues like this can be dealt with through a 
deliberative process. We question whether such a process could ‘accommodate’ a divergence from 
the analytical assumptions underlying an additive model. Nevertheless, we know of no research on 
these issues, so further work is required to guide best practice. 
No Connection between Criteria Scales and Weights 
Weights in additive value models express trade-offs between degrees of performance on the criteria 
scales. For instance, if a one-year response criterion measured on a scale of 10-90% has a weight of 
0.5; while an annual risk of serious adverse events (SAE) measured on a scale of 0-50% has a weight 
of 0.25, then increasing response from 10% to 90% would be twice as valuable as decreasing annual 
SAE risk from 50% to 0%. Willingness to trade-off SAEs for clinical benefit will depend on the 
increase in SAE and the improvement in response being traded. Accordingly, if stakeholders are to 
provide weights that reflect the trade-offs required by an additive model, they need to do so with scale 
ranges in mind. Weights should not be elicited independently of the range of consequences[6, 11]. 
Half of MCDAs where the weighting method was reported adopted weighting methods that ignored 
the range of consequences of the treatments evaluated[8]. In the illustration, criteria are scored on a 
pre-defined scale (1-5, with different points on the scale reflecting different levels of importance) and 
the criterion is defined as, for instance, just ‘improvement in efficacy/ effectiveness’ between ‘lower 
efficacy/effectiveness’ and ‘major improvement in efficacy/ effectiveness’. Although use of such a 
rating scale entails limitations like restricting the relative value of two criteria to a maximum ratio of 5 
to 1, here we focus on the challenges posed by not precisely defining the ranges of consequences. 
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The weight elicitation task adopted in the illustration is the equivalent of posing questions such as: 
How important is a change from ‘lower efficacy’ to ‘major improvement in efficacy’ compared to the 
change from ‘major budget impact’ to ‘no budget impact’? To answer this, one would need to 
understand how much health gain is represented by this ‘major improvement in efficacy’. In the 
illustration this is not clear, as the range of consequences is not precisely defined. Nor can it be 
inferred from the interventions being evaluated, as the weight elicitation is undertaken independently 
of the details of the interventions, which are revealed to stakeholders only after weights are elicited.  
While it is difficult to assess the face validity of weights, which are by their nature subjective, some of 
the weights elicited in the illustration warrant further scrutiny. For instance, ‘type of medical service’ 
received a slightly lower weight (0.067) than ‘improvement of safety/tolerability’ (0.070). Everything 
else being equal, this implies that stakeholders would prefer a treatment that offered symptom relief 
and a major improvement in safety to treatment that was curative but with a worse safety profile. 
Would stakeholders really not accept some safety risks to cure the disease? That seems unlikely. But, 
it is not possible to be definitive about this without further information: How severe is the disease 
being cured? What increased risk of adverse events is to be tolerated? How severe are these adverse 
events, and for what period are they experienced? Just as it is difficult to face validate the weights 
without more precision in the definition of criteria, so it is difficult to provide meaningful weights 
without this extra precision. 
It is possible to elicit preferences for precisely defined scale ranges with many different methods. 
Swing weighting very explicitly ensures that the scales ranges are considered in the elicitation 
process, as it asks the stakeholders to provide relative importance scores for ‘swings’ of 
performance[5]. However, defining precise scales ranges can be challenging when designing a 
generic MCDA framework to assess technologies that are still in development, as the range of 
consequences of the treatments to be evaluated is not known at the point at which weights are 
elicited. Instead it is necessary to either elicit weights across the range of possible performance 
against each criterion, or to abandon the goal of a generic MCDA framework. 
Using MCDA in Economic Evaluation  
An important objective of HTA is to estimate the differential benefits and costs of alternative options 
for particular groups of patients and to present this information in a way that informs funding 
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decisions. A number of examples of MCDA in the literature have sought to incorporate both the 
benefits and the costs into a single exercise[8]. For example, EVIDEM’s work with 10 medicines in 6 
therapeutic areas included both a range of benefit criteria (e.g. improvement of efficacy/effectiveness 
and disease severity) and economic criteria such as budget impact and cost-effectiveness[12]. This 
implies that how benefits and costs are ultimately traded-off is determined by the preferences of the 
stakeholder. There are a two broad concerns raised by this presumption.  
First, stakeholders’ preferences may not be the appropriate basis for evaluating the efficiency of 
technologies. Health care systems have agreed funding envelopes, and assuming that there are no 
obvious examples of unproductive current expenditure, there are always opportunity costs associated 
with decisions to fund a new and more costly intervention: forgone benefits that could have been 
generated elsewhere in the health care system. As such, benefit that may be forgone, rather than 
stakeholders’ willingness to pay (WTP), is the most appropriate way of thinking about the incremental 
cost of the new intervention, and those making funding decisions need to know whether the benefits 
of the new intervention outweigh the opportunity costs. 
Second, even if the goal is to elicit decision makers’ WTP, the concerns raised above undermine our 
confidence in how well this is being done. For example, providing a weight for ‘budget impact on the 
health plan’, defined as varying from ‘substantial’ to ‘substantial reduction’, seem an almost 
impossible task. This can be illustrated by interpreting the WTP for health gains implied by the 
weights in Table 1. Moving from ‘substantial budget reduction’ to ‘substantial budget impact’ is given a 
weight of 0.057. This compares with a weight of 0.086 for ‘improved efficacy or effectiveness’, moving 
from ‘lower efficacy/effectiveness’ to ‘major improvement in efficacy / effectiveness”. Put another way, 
this implies that stakeholders are willing to pay 51% more than the difference between a ‘substantial 
budget reduction’ and a ‘substantial budget impact’ to move from ‘lower efficacy / effectiveness’ to 
‘major efficacy improvement’. While we can’t claim that this is wrong, it is difficult to be confident 
about, or see how to validate this statement when faced with such imprecise definitions of criteria.  
Both these problems are avoided by leaving economic criteria off the list. The potential contribution of 
MCDA is to reflect the nuances of decision makers’ objectives in the form of a more complete benefit 
measure. The issues dealt with earlier in this paper need to be addressed in developing such a 
benefit function.  Furthermore, any fuller measure of benefit ought to be reflected in terms of an 
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empirical measure of opportunity costs[13]. Importantly, therefore, MCDA needs to be seen as a 
means of developing a more complete measure of benefit, hence complementing rather than 
substituting for efficiency (“cost-effectiveness”) analysis. 
Conclusion 
MCDA has potential for HTA: It can provide a more comprehensive measure of benefit than, for 
instance, the QALY. Its current application risks undermining this potential, however. We have 
highlighted three concerns with the approach adopted by many examples of MCDA for HTA: the 
additive models adopted ignore overlap and preferential dependence between criteria; the simple 
weighting techniques disregard the ranges of consequence; and the use of MCDA as a form of 
economic evaluation. 
Oftentimes the objectives of ‘practicality’ or ‘proximity’ to the thought process of decision makers are 
raised to justify the approaches employed. It is difficult to see, however, what is practical about 
adopting an additive model that favours a technology with no health gain. The researcher ought to 
challenge the decision makers’ thinking, helping them understand their objectives and how they relate 
and interact to generate value, and reflect these in the analytical framework.  
The application of MCDA to HTA raises other challenges that are not considered here[14]: Should 
criteria be fixed or varied between assessments? Which stakeholders should determine criteria and 
provide weights? How transparent should the criteria and weights be? How should we deal with 
heterogeneity in weights? It is important that these challenges are not compounded by ignoring 
established HTA principles and good practice guidelines. We hope this paper increases awareness of 
these, and what they mean for undertaking MCDA for HTA.  
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 Table 1: Example of the EVIDEM framework (adapted from Wahlster et al. 2015 [7]; https://www.evidem.org/evidem-framework/) 
Criterion Definition Scale Normali
weight* 
Relevance and validity of 
evidence 
Extent to which evidence on the proposed intervention is relevant to the decision-
making body (in terms of population, disease stage, comparator interventions, 
outcomes etc.) and valid with respect to scientific standards (i.e., study design 
etc.) and conclusions (agreement of results between studies).  
Low (0) – High (+3) 
relevance /validity 
0.076 
Completeness and 
consistency of reporting 
Extent to which reporting of evidence on the proposed intervention is complete 
(i.e., meeting scientific standards on reporting) and consistent with the sources 
cited. 
Many gaps/inconsistent (0) - 
Complete and consistent (+3) 
0.072 
Impact on other spending Impact of providing coverage for the proposed intervention on other expenditures 
(excluding intervention cost) such as hospitalization, specialist consultations, 
adverse events, long-term care, disability costs, lost productivity, caregiver time 
etc. 
Substantial additional other 
spending (0) - Substantial 
reduced spending (+3) 
0.061 
Cost-effectiveness of 
intervention 
Ratio of the incremental cost of the proposed intervention to its incremental benefit 
compared to alternatives.  
Not cost-effective (0) - Highly 
cost-effective (+3) 
0.068 
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Budget impact on health 
plan 
Net impact of covering the intervention on the budget of the target health plan 
(excluding other spending). Limited to cost of intervention (e.g. acquisition cost, 
implementation and maintenance cost). 
Substantial budget impact (0) 
- Substantial budget 
reduction (+3) 
0.057 
Type of medical service Nature of the clinical benefit provided by the proposed intervention at the patient-
level (e.g., symptom relief, prolonging life, cure). 
Minor service (0) - Major 
service (+3) 
0.067 
Public health interest Risk reduction provided by the proposed intervention at the population-level (e.g., 
prevention, reduction in disease transmission, reduction in the prevalence of risk 
factors). 
No risk reduction (0) - Major 
risk reduction (+3) 
0.072 
Improvement of patient 
reported outcomes 
Capacity of the proposed intervention to produce beneficial changes in patient-
reported outcomes (PROs) (e.g., quality of life) compared to alternative 
interventions. 
Worse PRO  (-3) - Major 
improvement (+3) 
0.082 
Improvement of safety 
and tolerability 
Capacity of the proposed intervention to produce a reduction in intervention-
related harmful or undesired health effects compared to alternative interventions. 
Lower safety/tolerability than 
comparators presented (-3) - 
Major improvement in safety/ 
tolerability (+3) 
0.070 
13 
 
Improvement of 
efficacy/effectiveness 
Capacity of the proposed intervention to produce a desired (beneficial) change in 
signs, symptoms or course of the targeted condition compared to alternative 
interventions 
Lower efficacy/effectiveness 
(-3) - Major improvement in 
efficacy/ effectiveness (+3) 
0.086 
Comparative interventions 
limitations 
Shortcomings of comparative interventions in their ability to prevent, cure, or 
ameliorate the condition targeted 
No or very minor limitations 
(0) - Major limitations (+3) 
0.074 
Clinical guidelines Concurrence of the proposed intervention with the current consensus of experts 
on what constitutes state-of-the-art practices  
No recommendation (0) - 
Strong recommendation (+3) 
0.067 
Size of the population 
affected by the disease 
Number of people affected by the condition (treated or prevented by the proposed 
intervention) among a specified population at a specified time 
Very rare disease (0) - 
Common disease (+3) 
0.063 
Disease severity Severity of the health condition with respect to mortality, disability, impact on 
quality of life, clinical course (i.e., acuteness, clinical stages). 
Not severe  (0) - Very severe 
(+3) 
0.080 
* A 5-point weight elicitation technique was used (1 = low importance; 5 = high importance). The average of stakeholder weights was used in the MCDA. 
 
